Growth hormone (GH) replacement therapy in adults with GH deficiency is still a challenge for the clinical endocrinologist and its implementation has still numerous difficulties and uncertainties. The decision to treat GH deficient adults requires a thoughtful and individualized evaluation of risks and benefits. Benefits have been found in body composition, bone health, cardiovascular risk factors, and quality of life. However, evidences for a reduction in cardiovascular events and mortality are still lacking, and treatment costs remain high. It is advisable to start treatment with low doses of GH, the goals being an appropriate clinical response, an avoidance of side effects, and IGF-I levels in the age-adjusted reference range. Although treatment appears to be overall safe, certain areas continue to require long-term surveillance, such as risks of glucose intolerance, pituitary/hypothalamic tumor recurrence, and cancer.

Management of GH treatment in adult GH deficiency

GASCO, Valentina;CAPUTO, Marina;LANFRANCO, Fabio;GHIGO, Ezio;Grottoli, Silvia
2017

Abstract

Growth hormone (GH) replacement therapy in adults with GH deficiency is still a challenge for the clinical endocrinologist and its implementation has still numerous difficulties and uncertainties. The decision to treat GH deficient adults requires a thoughtful and individualized evaluation of risks and benefits. Benefits have been found in body composition, bone health, cardiovascular risk factors, and quality of life. However, evidences for a reduction in cardiovascular events and mortality are still lacking, and treatment costs remain high. It is advisable to start treatment with low doses of GH, the goals being an appropriate clinical response, an avoidance of side effects, and IGF-I levels in the age-adjusted reference range. Although treatment appears to be overall safe, certain areas continue to require long-term surveillance, such as risks of glucose intolerance, pituitary/hypothalamic tumor recurrence, and cancer.
31
1
13
24
http://www.elsevier.com/inca/publications/store/6/2/3/0/0/1/index.htt
efficacy; GH deficiency; GH replacement therapy; safety; Endocrinology, Diabetes and Metabolism; Endocrinology
Gasco, Valentina; Caputo, Marina; Lanfranco, Fabio; Ghigo, Ezio; Grottoli, Silvia
File in questo prodotto:
File Dimensione Formato  
Gasco et al 2017 con copertina.doc

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.27 MB
Formato Microsoft Word
1.27 MB Microsoft Word Visualizza/Apri
Figure 1 Gasco.ppt

Accesso aperto

Descrizione: Gasco et al. Fig. 1
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 62.5 kB
Formato Microsoft Powerpoint
62.5 kB Microsoft Powerpoint Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1644424
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact